Resverlogix Corp. (RVX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Resverlogix Corp. (RVX) has a cash flow conversion efficiency ratio of 0.011x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-972.79K ≈ $-703.70K USD) by net assets (CA$-90.31 Million ≈ $-65.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See RVX net asset quality index to measure how much of total assets are equity-financed.
Resverlogix Corp. - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Resverlogix Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check RVX cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Resverlogix Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Resverlogix Corp. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Earlypay Ltd
AU:EPY
|
0.039x |
|
KR1 PLC LS -0019
F:K4H
|
N/A |
|
KNW Co. Ltd
KQ:105330
|
0.026x |
|
Smart Logistics Global Limited Ordinary Shares
NASDAQ:SLGB
|
-0.051x |
|
ARENA.PL S.A. ZY -50
F:8G6
|
-0.001x |
|
Diamond Citra Propertindo PT
JK:DADA
|
0.016x |
|
Daishin Information & Communications Co.Ltd
KQ:020180
|
-0.060x |
|
TAS Offshore Bhd
KLSE:5149
|
0.143x |
Annual Cash Flow Conversion Efficiency for Resverlogix Corp. (2001–2025)
The table below shows the annual cash flow conversion efficiency of Resverlogix Corp. from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Resverlogix Corp..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$-88.80 Million ≈ $-64.24 Million |
CA$-3.73 Million ≈ $-2.69 Million |
0.042x | -11.77% |
| 2024-12-31 | CA$-81.73 Million ≈ $-59.13 Million |
CA$-3.89 Million ≈ $-2.81 Million |
0.048x | +35.51% |
| 2023-12-31 | CA$-74.47 Million ≈ $-53.87 Million |
CA$-2.61 Million ≈ $-1.89 Million |
0.035x | -41.26% |
| 2022-12-31 | CA$-59.28 Million ≈ $-42.88 Million |
CA$-3.54 Million ≈ $-2.56 Million |
0.060x | -55.43% |
| 2021-12-31 | CA$-59.87 Million ≈ $-43.31 Million |
CA$-8.02 Million ≈ $-5.80 Million |
0.134x | +121392.30% |
| 2020-12-31 | CA$-39.90 Million ≈ $-28.86 Million |
CA$-4.40K ≈ $-3.18K |
0.000x | -99.96% |
| 2019-12-31 | CA$-64.11 Million ≈ $-46.38 Million |
CA$-17.34 Million ≈ $-12.55 Million |
0.271x | +15.07% |
| 2018-12-31 | CA$-207.72 Million ≈ $-150.26 Million |
CA$-48.83 Million ≈ $-35.33 Million |
0.235x | -21.73% |
| 2017-12-31 | CA$-83.68 Million ≈ $-60.53 Million |
CA$-25.13 Million ≈ $-18.18 Million |
0.300x | +34.58% |
| 2016-12-31 | CA$-101.57 Million ≈ $-73.47 Million |
CA$-22.67 Million ≈ $-16.40 Million |
0.223x | -41.21% |
| 2015-12-31 | CA$-56.43 Million ≈ $-40.82 Million |
CA$-21.42 Million ≈ $-15.50 Million |
0.380x | +229.32% |
| 2014-12-31 | CA$-73.73 Million ≈ $-53.33 Million |
CA$-8.50 Million ≈ $-6.15 Million |
0.115x | -44.80% |
| 2013-12-31 | CA$-63.22 Million ≈ $-45.73 Million |
CA$-13.20 Million ≈ $-9.55 Million |
0.209x | -78.75% |
| 2012-12-31 | CA$-29.50 Million ≈ $-21.34 Million |
CA$-29.00 Million ≈ $-20.98 Million |
0.983x | +111.21% |
| 2011-12-31 | CA$2.74 Million ≈ $1.98 Million |
CA$-24.03 Million ≈ $-17.38 Million |
-8.766x | -95.92% |
| 2010-12-31 | CA$4.30 Million ≈ $3.11 Million |
CA$-19.24 Million ≈ $-13.92 Million |
-4.474x | -8.91% |
| 2009-12-31 | CA$4.46 Million ≈ $3.23 Million |
CA$-18.34 Million ≈ $-13.26 Million |
-4.108x | -266.55% |
| 2008-12-31 | CA$11.61 Million ≈ $8.40 Million |
CA$-13.01 Million ≈ $-9.41 Million |
-1.121x | +68.96% |
| 2007-12-31 | CA$5.44 Million ≈ $3.94 Million |
CA$-19.65 Million ≈ $-14.21 Million |
-3.611x | -137.13% |
| 2006-12-31 | CA$-1.02 Million ≈ $-738.42K |
CA$-9.93 Million ≈ $-7.18 Million |
9.724x | +1749.37% |
| 2005-12-31 | CA$7.48 Million ≈ $5.41 Million |
CA$-4.41 Million ≈ $-3.19 Million |
-0.590x | -166.26% |
| 2004-12-31 | CA$9.84 Million ≈ $7.12 Million |
CA$-2.18 Million ≈ $-1.58 Million |
-0.221x | +35.03% |
| 2003-12-31 | CA$2.60 Million ≈ $1.88 Million |
CA$-885.04K ≈ $-640.23K |
-0.341x | +29.20% |
| 2002-12-31 | CA$942.21K ≈ $681.58K |
CA$-453.56K ≈ $-328.10K |
-0.481x | -1038.52% |
| 2001-12-31 | CA$259.64K ≈ $187.82K |
CA$-10.98K ≈ $-7.94K |
-0.042x | -- |
About Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID… Read more